(NASDAQ: VOR) Vor Biopharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.33%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.78%.
Vor Biopharma's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast VOR's revenue for 2026 to be $1,583,538,888, with the lowest VOR revenue forecast at $1,583,538,888, and the highest VOR revenue forecast at $1,583,538,888. On average, 1 Wall Street analysts forecast VOR's revenue for 2027 to be $12,327,533,531, with the lowest VOR revenue forecast at $12,327,533,531, and the highest VOR revenue forecast at $12,327,533,531.
In 2028, VOR is forecast to generate $22,099,868,714 in revenue, with the lowest revenue forecast at $22,099,868,714 and the highest revenue forecast at $22,099,868,714.